Guided Therapeutics, Inc. (GTHP) Stock Price & Analysis
Guided Therapeutics, Inc. (GTHP) — price $0.105 (-4.55%), as of the Nov 19, 2026 trading session; market cap $10.1M.
Educational signal · not a buy or sell recommendation · How to read this
Guided Therapeutics, Inc. · GTHP
Guided Therapeutics, Inc. is a medical technology company focused on developing and commercializing the LuViva advanced cervical scan. LuViva is a non-invasive point-of-care device designed for the early detection of cervical cancers and precancers.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.105 | |
| Change on the day | -4.55% | |
| Market capitalisation | $10.1M | — |
| Shares traded on the day | 15.1K |
Price & events
Other perspectives
Council score for Guided Therapeutics (GTHP): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Guided Therapeutics (GTHP), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Guided Therapeutics, Inc. (GTHP) is the company analyzed here. It employs 3 people. In Q4 FY2025 it reported revenue of $590,000 and net income of -$1M. The market values it at $10.1M.
What do the latest results show for Guided Therapeutics (GTHP)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $590,000.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $590,000 | -$1M | -$0.01 (diluted) |
| Q3 FY2025 | $60,000 | -$742,000 | -$0.01 (diluted) |
What are the financial strengths and risks for Guided Therapeutics (GTHP)?
Short answer · as of
The distress and quality screens read Piotroski F 2. Trailing ratios: ROE 66.0% · current ratio 0.09 · earnings yield -28.0% · free-cash-flow yield -11.3%.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 30, 2026
- Transactions
- 2
- Identified insiders
- 1
- Purchases
- 0
- Sales
- 0
- Other transactions
- 2
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GTHP in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GTHP in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Guided Therapeutics (GTHP)?
What Investors Ask About Guided Therapeutics (GTHP)
These answers are editorial: 1 of these 8 answers is drawn from the GTHP research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is GTHP a good stock to buy?
Stock Expert AI does not rate GTHP buy, sell or hold. Guided Therapeutics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the GTHP stock price today?
The last price recorded for Guided Therapeutics, Inc. (GTHP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about GTHP stock?
There is currently no available analyst coverage for GTHP stock. Given its OTC listing and micro-cap status, Guided Therapeutics may not attract significant attention from major research firms.
What are the key factors to evaluate for GTHP?
Evaluate GTHP on fundamentals, analyst consensus, and risk factors. Effective marketing campaigns can also help to overcome resistance to new technologies. Not financial advice.
How frequently does GTHP data refresh on this page?
GTHP's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven GTHP's recent stock price performance?
Guided Therapeutics, Inc. (GTHP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Non-invasive cervical cancer detection. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GTHP overvalued or undervalued right now?
Guided Therapeutics, Inc. (GTHP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GTHP before investing?
Before investing in Guided Therapeutics, Inc. (GTHP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 9 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com